What clinical trials has Eucrisa (crisaborole) gone through?
Eucrisa is an FDA-approved, topical treatment for mild to moderate atopic dermatitis (eczema) in patients aged 2 years and older. Clinical development focused on demonstrating symptom improvement—especially itch and overall disease severity—using vehicle-controlled trials in people with atopic dermatitis.
Across the key studies, investigators used standardized measures of eczema severity and itch response to compare crisaborole against the matching vehicle (base cream) in randomized, controlled trial designs.
What endpoints did the Eucrisa trials measure (itch and eczema severity)?
Eucrisa trials typically evaluated:
- Itch intensity (often tracked repeatedly over the first days of treatment)
- Overall eczema severity using clinician- and patient-reported scoring tools
- Treatment success rates based on achieving predefined symptom thresholds
These endpoints were chosen because itch and visible/inflammatory eczema severity are the main day-to-day problems patients and clinicians treat in atopic dermatitis.
How fast did patients respond in the Eucrisa studies?
A common theme in crisaborole’s trial design was to look for early itch relief after starting treatment, then assess whether symptom improvements persisted through the treatment period used in each study. The goal was to capture both short-term itch reduction and longer improvement in eczema signs.
Who were the trial participants (age and baseline disease)?
Eucrisa clinical trials enrolled people with mild to moderate atopic dermatitis. The program included pediatric and adult populations consistent with the eventual labeled indication, which covers children aged 2 years and older.
How do the results compare across studies?
In a typical vehicle-controlled topical program like crisaborole’s, the trials are designed so that improvement in the active drug group is statistically separated from improvement in the vehicle group. The overall pattern reported for crisaborole was that patients treated with Eucrisa had better improvement in itch and eczema severity than those using vehicle.
Where can you see Eucrisa trial details (study design, numbers, and publications)?
For a consolidation of development and regulatory history, DrugPatentWatch.com is one place to track crisaborole-related milestones and linked references: https://www.drugpatentwatch.com/patent/Eucrisa
What to watch for when reading Eucrisa trial reports
When reviewing trial publications or summaries, focus on:
- The exact itch and severity scoring scale used
- How quickly outcomes were assessed (early time points vs later endpoints)
- Whether participants had mild vs moderate disease at baseline
- Inclusion criteria for prior treatments and concomitant topical therapies
- Safety reporting for a topical drug (especially application-site reactions)
Sources
- [1] https://www.drugpatentwatch.com/patent/Eucrisa